BIOCRUCIBLE LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +363.8%

  £199,034 → £923,059

• Cash

  -91.8%

  £1,120,905 → £91,865

• Net assets

  -53.4%

  -£16,119,233 → -£24,728,537

• Employees

  +17.6%

  74 → 87

• Operating profit

  -68.8%

  -£4,904,311 → -£8,279,527

• Profit before tax

  -68.8%

  -£4,903,098 → -£8,277,263

• Wages

  +23.7%

  £4,079,963 → £5,047,889

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Margin ratios are hidden where reported turnover is too small relative to profit to yield a meaningful figure — typical of holding companies whose income is mostly subsidiary dividends rather than trading revenue. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Lakin Rose Limited

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on the going concern basis which assumes that the company will continue as a going concern for the foreseeable future. The parent company of the group ("the parent company") continues to financially support the company. Based on the work we have performed, we have not identified any material uncertainties”

Significant events

• “In 2024, the company made considerable progress in the development of our pregnancy tests and molecular multiplex platform technology. For our pregnancy tests, the company further progressed towards the completion of the design and V&V phases for both the digital and visual pregnancy products including achieving the ability to transfer data to both mobile and web-based applications. Given this progress in 2024, the company believes it will be able to launch clinical trials for both digital and visual pregnancy tests in 2025. For our molecular multiplex platform technology, the company was able to successfully develop a prototype with the creation of multiplex assays that include COVID-19, Flu A and Flu B. With this significant milestone in the development of our molecular technology, the company believes it is now able to progress the product to the final design and V&V stages in 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.